Skip to content
Open access

Performance evaluation of a novel size-based microfluidic platform for rare cell detection in blood and malignant effusions

Oct 2026 · The journal of liquid biopsy · Vol 14 · 0 citations · 46 references
Medicine

Abstract

Background Circulating tumour cells (CTCs) are promising minimally invasive biomarkers of tumour dissemination and disease biology, but low abundance and phenotypic heterogeneity make them challenging to isolate, particularly in non-small cell lung cancer (NSCLC). Physical cell-selection approaches based on size and deformability may facilitate recovery of heterogeneous tumour populations. This study evaluated the performance of the Bio-Rad™ Genesis Cell Isolation System, a microfluidic platform based on these properties, across different tumour phenotypes and liquid biopsy sample types. Methods Recovery capabilities of the Genesis enrichment and enumeration workflows were evaluated using the EpCAM-high H1975 and EpCAM-low H1299 NSCLC cell lines, and a standardised spike-in protocol. Following optimisation, peripheral (Pe) and pulmonary vein (PV) blood from patients with resectable NSCLC, ascites from patients with advanced gynaecological cancers, and matched Pe blood and pleural fluid (PF) from patients with advanced NSCLC were assessed using the enumeration workflow. Tumour cells were identified by immunofluorescence. Results High and consistent recovery was observed for both H1975 and H1299 cells, independent of EpCAM expression, with mean recovery of 68.81 ± 10.53% and 65.17 ± 9.53% using enrichment, and 70.05 ± 10.06% and 80.51 ± 5.72% using enumeration, respectively. CTCs were detected in 2/11 Pe blood and 3/4 PV samples from patients with resectable NSCLC. Ascites contained 69-1113 ascites epithelial cells (AECs)/mL, with 89.31–98.21% occurring within clusters. Pleural epithelial cells (PECs) were identified in 3/3 PF samples from advanced NSCLC patients (16.3–132 cells/mL), predominantly as clusters, but were absent from matched Pe blood. Notably, PECs were detected in PF despite negative cytology in one patient. Conclusions The Genesis demonstrated consistent, EpCAM-independent recovery, across NSCLC models and enabled tumour cell and cluster detection across diverse clinical liquid biopsy specimens. Its ability to analyse tumour-rich fluids, including a cytology-negative PF sample, supports further investigation as a versatile and complementary platform for rare cell detection and characterisation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.